Related Experiment Videos
[Basic principles of hormone replacement therapy in the postmenopause].
1King's College Hospital, Dept of Family Planning, London, UK. martina@doeren.fsnet.co.uk
Therapeutische Umschau. Revue Therapeutique
|November 18, 2000
Summary
Postmenopausal hormone therapy, including various estrogens and progestogens, effectively manages symptoms and prevents bone loss. Non-oral estradiol may benefit specific patient groups, while progestogens are crucial for endometrial protection.
Area of Science:
- Endocrinology
- Gynecology
- Pharmacology
Background:
- Postmenopausal hormone therapy (PHT) utilizes various estrogen formulations to manage climacteric symptoms and bone loss.
- Estrogens like 17 beta-estradiol, conjugated equine estrogens, esterified estrogens, and estriol are available in oral and non-oral forms.
- Progestogens are essential for endometrial protection when estrogen therapy is administered.
Purpose of the Study:
- To review current postmenopausal replacement therapy options, including different estrogen types and administration routes.
- To discuss the role of progestogens in endometrial protection and compare different PHT regimens.
- To evaluate the efficacy and safety of tibolone as a PHT option.
Main Methods:
- Review of clinical use of oral and non-oral estrogen preparations for postmenopausal replacement therapy.
- Analysis of dosages for symptom relief and bone mineral density maintenance.
- Examination of the necessity and optimal use of progestogens for endometrial protection.
- Evaluation of tibolone as an alternative PHT option.
Main Results:
- Daily doses of estradiol, conjugated equine estrogens, or estriol can alleviate climacteric symptoms and reduce bone resorption.
- Non-oral estradiol administration may offer metabolic advantages for diabetic women or those with hypertriglyceridemia.
- Progestogen use for 10-14 days per month is effective in preventing endometrial hyperplasia.
- Tibolone shows promise for symptom management and bone loss prevention, with comparable amenorrhea rates to continuous combined therapy.
Conclusions:
- Various estrogen formulations and administration routes are effective for postmenopausal hormone therapy.
- Progestogens are critical for endometrial safety, and their timing influences hyperplasia risk.
- Non-oral routes may offer specific benefits, and tibolone presents a viable alternative PHT option.
- Treatment selection depends on individual patient factors, including acceptance of withdrawal bleeding.